Summary: Platelet glycoprotein (GP) IIb/IIIa inhibitors have been shown to be effective in reducing thrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI) and when used as medical therapy in patients with unstable angina/non-ST-segment elevation myocardial infarction (MI). Recent findings include dramatic preventive benefits in the setting of coronary stent deployment and a significant long-term preventive effect on mortality. The benefits of GP IIb/IIIa receptor inhibition suggest the utility of adopting routine use of these agents in critical pathways of unstable angina/non-ST-segment elevation MI and PCI. Because cost constraints may limit use of these agents, however, targeting treatment based on patient risk assessment may be warranted.
Introduction
Platelet glycoprotein (GP) IIb/IIIa receptor inhibitors preclude platelet function by occupying the fibrinogen binding site on the platelet surface, preventing cross-linking of platelets by fibrinogen during thrombus formation induced by plaque disruption or rupture. [1] [2] [3] Inhibition of platelet aggregation with GP IIb/IIIa receptor inhibitors has been shown to improve clinical outcome in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI). [4] [5] [6] [7] [8] GP IIb/IIIa receptor inhibitor treatment in patients undergoing PCI has been found to reduce the incidence of death, myocardial infarction (MI), and/or urgent revascularization in high-risk patients, those undergoing elective procedures, patients with unstable angina, patients with acute ST-segment elevation MI, and in those undergoing coronary stent deployment; use of GP IIb/ IIIa receptor inhibitors in this setting has become a new therapeutic standard. In addition, GP IIb/IIIa receptor inhibitors are approved for use as initial treatment in patients with unstable angina/non-ST-segment elevation MI, having been associated with significant reductions in clinical endpoints regardless of whether patients are managed medically or subsequently undergo PCI or surgical intervention.
Overall, the benefits of platelet receptor inhibition shown by these agents in clinical trials have served to highlight the importance of acute thrombosis and platelet aggregation in acute coronary syndromes and have underscored the need to determine how GP IIb/IIIa receptor inhibition is to be best fit into critical pathways for the management of patients with acute coronary syndromes. The current article describes experience with GP IIb/IIIa receptor inhibitor treatment in interventional and medical therapy patient populations, focusing on use in the setting of unstable angina/non-ST-segment elevation MI and describing initial attempts to incorporate such treatment into critical pathways at the author's institution. The use and potential role of GP IIb/IIIa receptor inhibitors in the setting of acute ST-segment elevation MI is extensively discussed in another article in this supplement.
MI, or urgent revascularization at 30 days, compared with standard treatment with aspirin and heparin (Fig. 1A ). These benefits have been shown to be durable (Fig. 1B) , with significant prevention of thrombotic events observed up to 3 years in the EPIC population. 10 The more recent Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial compared abciximab plus stenting or coronary angioplasty with stenting plus placebo in all patients receiving aspirin and heparin. 5 The results of this trial, the largest stenting trial reported to date, are important because stenting has become common practice in coronary intervention in the past several years and now represents state-of-theart interventional treatment. EPISTENT showed that the addition of abciximab to aspirin and heparin in patients undergoing coronary stent deployment resulted in a 50% relative reduction and a 5.5% absolute reduction in rates of death, MI, or urgent revascularization at 30 days (p < 0.001) compared with stenting alone (Fig. 2) . These benefits have also proven to be durable. Compared with the stent group receiving placebo, patients receiving stent/abciximab exhibited a 5.7% absolute reduction in death, MI, or urgent revascularization, a 5.8% absolute reduction in death or MI, and a 5.3% absolute reduction in death, MI, or target vessel revascularization at 6 months. 12 At 1 year, a mortality benefit was seen: mortality was reduced by 58% (2.4% for the placebo plus stent group vs. 1.0% for the abciximab plus stent group; p = 0.03). 13 The benefits of GP IIb/IIIa receptor inhibition in patients with unstable angina undergoing PCI appear to result from both prevention of platelet aggregation during iatrogenic plaque disruption and stabilization of the complex plaques prior to intervention. As shown in the CAPTURE trial of abciximab, 11 administration of abciximab for up to 24 h prior to intervention resulted in a significant reduction in rates of both preintervention MI and intraprocedural MI, the latter of which accounted for the majority of events (Fig. 3) . The ability of these agents to reduce thrombotic events appears to be explained by their ability to resolve thrombi. For example, data from a subset of CAPTURE patients 14 indicate that the addition of abciximab to aspirin and heparin resulted in a significantly greater frequency of thrombus resolution prior to coronary intervention (42.2 vs. 20.5%; p = 0.038). The notion that improved clinical outcome with these agents is consequent upon both inhibition of platelet aggregation and thrombus resolution is borne out by three major studies with other GP IIb/IIIa receptor inhibitors as medical therapy in patients with unstable angina/non-ST-segment elevation MI. In the Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) trial, 15 treatment with the GP IIb/IIIa receptor inhibitor tirofiban was associated with a reduction of 32% in the primary endpoint of death, MI, or recurrent ischemia at 48 h (3.8% for the tirofiban group vs. 5.9% for the heparin group; p = 0.007) compared with aspirin and heparin alone, with PCI being performed in only 1.9% of patients within this time period. By 30 days, however, there was no significant difference between tirofiban and placebo groups with regard to rates of the composite endpoint (15.9 vs. 17.1% for tirofiban and placebo, respectively; p = 0.11). In the PRISM in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial, 8 which included patients with more severe clinical expression of unstable angina, tirofiban plus heparin and aspirin treatment was associated with a 32% reduction in the primary endpoint of death, MI, or recurrent ischemia at 7 days (17.9 vs. 12.9%; p = 0.004), including results in patients who subsequently underwent intervention. Rates of the composite endpoint were also significantly reduced in the tirofiban group at 30 days and 6 months.
In the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, 7 treatment with the GP IIb/IIIa receptor inhibitor eptifibatide was associated with a 10% reduction in the primary endpoint of death or MI at 30 days (14.2% for the eptifibatide group vs. 15.7% for the placebo group; p = 0.042).
A recent meta-analysis of the effect of GP IIb/IIIa receptor inhibitor treatment on the rate of death or MI in the interventional or medical management setting in trials reported by mid-1998 indicates a highly significant benefit of such treatment in a combined population of more than 30,000 patients (Fig. 4) . 13 The ability of GP IIb/IIIa receptor inhibition to reduce thrombotic events in both patients with acute coronary syndromes and in those undergoing PCI indicates the potential benefit of including treatment with these agents across the entire spectrum of patients with unstable angina/non-STsegment elevation MI.
Reduction in Mortality in Abciximab Trials
It is important to note that although GP IIb/IIIa receptor inhibitor treatment has been associated with reductions in thrombotic events in clinical trials, there has been no clear indication of reduced mortality alone until recently. Indeed a recent meta-analysis of all trials 16 showed no benefit on mortality across all agents. However, a meta-analysis of 5,000 patients who received abciximab after PCI showed that abciximab treatment was associated with a 30% reduction in mortality over the course of follow-up (hazard ratio 0.70, 95% confidence interval 0.52-0.94; p = 0.016). 17 The association of abciximab treatment with reduced mortality indicated by this analysis has been strikingly borne out by recently reported long-term findings in the EPISTENT trial. 13 These data show that abciximab/stent treatment was associated with a 58% relative reduction in mortality at 1 year compared with placebo/ stent treatment among all randomized patients (1.0 vs. 2.4%, p = 0.03). An updated mortality meta-analysis, including the EPISTENT outcomes (a total of more than 6,500 patients), indicates a 36% mortality risk reduction (p = 0.002) among patients receiving abciximab (Fig. 5) . 18 There is some speculation on the etiology of abciximab's mortality benefit when no other GP IIb/IIIa receptor inhibitors have shown such effect. Possibilities that have been raised include greater reductions in the occurrence of periprocedural MI, as well as physiologic responses that may be related to the vitronectin receptor or perhaps even MAC 1 as opposed to GP IIb/IIIa receptor blockade. Abciximab's long duration of platelet inhibition may also be responsible for the reduction in long-term mortality.
It is noteworthy that such benefits do not occur at the cost of increased bleeding risk, the adverse effect that has been of primary concern with GP IIb/IIIa receptor inhibition. The results of EPISTENT also reconfirmed earlier data that showed that there is no increased risk of major bleeding with GP IIb/ IIIa receptor inhibitor treatment when reduced-dose, weightadjusted heparin regimens are used (Fig. 6 ). After observation of increased bleeding risk with standard heparin regimens in the EPIC trial, 4 use of a lower dose heparin regimen in combination with abciximab in EPILOG 6 was shown to result in bleeding rates comparable to those observed with placebo, and an important interaction of GP IIb/IIIa receptor inhibition with heparin was identified. This experience supports the general principle that dosing of components of an antithrombotic regimen must be reevaluated when an additional antithrombotic agent is added.
Incorporation of GP IIb/IIIa Receptor Inhibitor Treatment in Critical Pathways
The critical pathways for acute coronary syndromes currently in place at Brigham and Women's Hospital in Boston are shown in Figure 7A ; the newly revised critical pathway for unstable angina/non-ST-segment elevation MI is shown in Figure 7B . In terms of initial management, the focus for lowrisk patients is on making a clear diagnosis. For those with unstable angina/non-ST-segment elevation MI, GP IIb/IIIa receptor inhibitor treatment has been incorporated into initial management. Options in the use of this treatment include beginning treatment upon admission or starting patients who will be rapidly moved to the catheterization laboratory on aspirin and heparin, with the GP IIb/IIIa receptor inhibitor added in those undergoing coronary intervention.
Much of the data shown for trials investigating GP IIb/IIIa receptor inhibition as medical management in unstable angina include outcomes in patients who subsequently underwent coronary intervention. Indeed, much of the benefit of GP IIb/ IIIa blockade in the PRISM, PRISM-PLUS, and PURSUIT trials was driven by the subpopulation that underwent percutaneous revascularization. 7 However, as shown by a breakdown of data from PRISM-PLUS, 8 benefits in reducing 30-day rates of death or MI were observed in subsets of patients who received no intervention, underwent PCI, or required coronary artery bypass grafting (Fig. 8) . A similar trend was observed in the PURSUIT trial. 7 The ability of these agents to stabilize patients regardless of treatment strategy may be an important factor in deciding how such treatment is to be incorporated into management pathways.
Cost Effectiveness
The benefits observed with GP IIb/IIIa receptor inhibitor treatment across the spectrum of acute coronary syndromes argue for their routine use. However, cost constraints are often cited as a factor motivating limited use based on risk assessment. Currently, there are few published data on cost effectiveness of GP IIb/IIIa receptor inhibitor treatment. A cost analysis of treatment in patients in the EPIC trial 19 showed that cost savings associated with reduced need for reintervention during initial hospitalization were virtually offset by cost of the excess bleeding complications observed in the trial. At 6 months, the lower rates of rehospitalization, catheterization, and reintervention in abciximab patients resulted in a cost savings that resulted in a net cost of $200 per patient when the abciximab drug cost was included.
Analysis of the 470 patients with unstable angina in EPIC showed a relative cost of $264 per patient during initial hospitalization and a net savings of $763 per patient including drug cost at 6 months. 20 These findings suggest that cost effectiveness of abciximab may be relatively increased in patients with unstable angina. Indeed, a cost-effectiveness analysis combining data from major abciximab trials prior to EPISTENT indicates a cost of $18,000 per life-year-saved (data on file, Centocor, Inc.); this value compares quite favorably with cost per life-year-saved of other accepted standard therapies. For example, it is lower than the estimated $32,000 cost per lifeyear-saved for tissue plasminogen activator compared with streptokinase.
Despite the optimistic economic data and the demonstration of benefits of GP IIb/IIIa receptor inhibitor treatment across risk strata, there may be economic advantages to targeting the use of GP IIb/IIIa receptor inhibitors to high-risk patients. Several different approaches have been taken to assess risk in acute coronary syndrome patients. The Thrombolysis in Myocardial Infarction (TIMI)-III trial 21, 22 and other trials have established ST-segment depression and transient ST-segment elevation as important risk factors. Troponin levels have also been shown to be useful in the identification of patients at elevated risk of adverse outcome. In the CAPTURE trial, prior to intervention, rates for death or MI for troponin-positive patients were 0% for the abciximab group versus 6.1% for the placebo group (p = 0.01). 23 During intervention, all patients benefited equally from abciximab, and rates were 2% for the abciximab group versus 10% for the placebo group (p = 0.01). At 6 months, the benefit was sustained (9.5% for the abciximab group versus 25.5% for the placebo group; p = 0.004). Positive troponin status at baseline was predictive of risk of death or MI prior to intervention, with abciximab treatment associated with a dramatic decrease in event rate for up to 6 months. Patients who were troponin negative had very few events and, as such, little benefit from abciximab, underscoring the need to identify patients appropriately who will derive the most benefit from the drug.
Other high-risk patients include those refractory to medical therapy and those with compromised left ventricular function. The CAPTURE trial demonstrated that GP IIb/IIIa blockade is beneficial as a pretreatment and as adjunctive treatment to percutaneous transluminal coronary angioplasty in refractory unstable angina patients.
As noted, data from the PRISM-PLUS and CAPTURE trials indicate that patients benefit from GP IIb/IIIa receptor inhibitor treatment during the preintervention period and in cases in which no intervention is performed. The issue of whether an invasive approach or conservative medical management results in superior clinical outcome in patients with unstable angina/non-ST-segment elevation MI remains undecided. The TIMI-IIIB trial 24, 25 showed that coronary intervention was associated with a significantly lower rate of rehospitalization for patients with angina than for patients who received conservative management, with no differences in the rates of death/ MI or death at 1 year. The Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) trial 26 showed no difference between the approaches in rates of death/MI at follow-up but did show a significant reduction in 1-year mortality in patients who received conservative management. It is important to note that stenting was not incorporated into the TIMI-IIIB and VANQWISH trials, and stenting is a prime consideration in clinical practice.
The Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS)-TIMI-18 study 27 is examining the issue of how best to triage patients to a treatment strategy when routinely incorporating GP IIb/IIIa receptor inhibition into their management. As shown in Figure 9 , patients with unstable angina/non-ST-segment elevation MI are treated with aspirin, heparin, and the GP IIb/IIIa receptor inhibitor tirofiban and randomized to early invasive or conservative treatment.
It should be noted that the inclusion of low-molecularweight heparin as potential treatment for unstable angina/ non-ST-segment elevation patients in our critical pathway reflects recent findings 28, 29 indicating the superiority of low-molecular-weight heparin over standard unfractionated heparin. Several studies are currently under way to examine the combination of GP IIb/IIIa receptor inhibition with lowmolecular-weight heparin.
It is expected that optimal antithrombotic therapy will involve the combination of a low-molecular-weight heparin and a GP IIb/IIIa receptor inhibitor to improve both the anticoagulant and antiplatelet therapy for patients with unstable angina/non-ST-segment elevation MI.
Conclusions
GP IIb/IIIa receptor inhibitors have been shown to be effective in reducing thrombotic events in patients with acute coronary syndromes and in those undergoing PCI. Recent findings include marked reductions in event rates in stented patients with GP IIb/IIIa receptor inhibition and significant reductions in mortality in patients undergoing PCI who receive abciximab. The ability of these agents to prevent thrombotic events in patients with unstable angina/non-STsegment elevation MI across all risk strata and in both the medical management and interventional settings suggests that their use should be routinely adopted into critical pathways for such patients. However, in situations where costs are an issue, one means of optimizing the cost effectiveness of these agents is to utilize risk assessment so that therapy can be targeted at higher risk patients. 
